ArticleBiogerontology2026
Oxidative stress in frailty among older adults: are malondialdehyde and superoxide dismutase the key biomarkers?
Article in Biogerontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Frailty is a significant health issue among older adults. Oxidative stress (OS), indicated by elevated malondialdehyde (MDA) levels and reduced superoxide dismutase (SOD) activity, is implicated in age-related diseases. This study aims to explore the relationship between OS biomarkers, MDA and SOD, and frailty among older adults. This study investigated the association between MDA, SOD, and frailty in 3181 older adults from the Chinese Longitudinal Healthy Longevity Survey (CLHLS). Frailty was assessed using a 37-variable frailty index. Logistic regression and restricted cubic spline (RCS) analysis were employed to examine the relationship between OS biomarkers and frailty, adjusting for demographic, socioeconomic, lifestyle, and physically relevant factors. This study has found that higher MDA levels were significantly associated with increased frailty risk (OR = 1.06, 95% CI: 1.03-1.09), while SOD activity showed no independent association. The threshold point for MDA was 3.37 (P = 0.003). This study highlights that MDA is independent OS biomarker related to frailty in community-dwelling older adults, suggesting plasma MDA as OS biomarker could potentially aid in the identification and clinical management of frailty.
Indexed as
Identifiers
41677964What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.